Self-Monitoring of Blood Glucose in Glucagon-Like Peptide-1–Based Treatment Approaches

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Diabetes Spectrum

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/diaspect.26.2.107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone

  2013cited by this paper
• American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis.

  2012cited by this paper
• Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.

  2012cited by this paper
• Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.

  2012cited by this paper
• The Role of Self-Monitoring of Blood Glucose in Glucagon-like Peptide-1-Based Treatment Approaches: A European Expert Recommendation

  2012cited by this paper
• Consensus Report: The Current Role of Self-Monitoring of Blood Glucose in Non-Insulin-Treated Type 2 Diabetes

  2011cited by this paper
• Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

  2011cited by this paper
• Structured Self-Monitoring of Blood Glucose Significantly Reduces A1C Levels in Poorly Controlled, Noninsulin-Treated Type 2 Diabetes

  2011cited by this paper
• Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study 1

  2011cited by this paper
• Addressing Schemes of Self-Monitoring of Blood Glucose in Type 2 Diabetes: A European Perspective and Expert Recommendation

  2011cited by this paper
• Structured Self-Monitoring of Blood Glucose Signi fi cantly Reduces A 1 C Levels in Poorly Controlled , Noninsulin-Treated Type 2 Diabetes Results from the Structured Testing Program study

  2011cited by this paper
• ROSES: role of self‐monitoring of blood glucose and intensive education in patients with Type 2 diabetes not receiving insulin. A pilot randomized clinical trial

  2011cited by this paper
• Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review

  2011cited by this paper
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  2010cited by this paper
• A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin

  2010cited by this paper
• Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

  2010cited by this paper
• Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature

  2010cited by this paper
• Benefits of self‐monitoring blood glucose in the management of new‐onset Type 2 diabetes mellitus: The St Carlos Study, a prospective randomized clinic‐based interventional study with parallel groups

  2010cited by this paper
• Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.

  2010cited by this paper
• DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

  2010cited by this paper
• Comparison of vildagliptin and thiazolidinedione as add‐on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, type 2 diabetes study

  2009cited by this paper
• Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

  2009cited by this paper
• The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis.

  2009cited by this paper
• Self-Monitoring of Blood Glucose (SMBG) in Insulin- and Non–Insulin-Using Adults with Diabetes: Consensus Recommendations for Improving SMBG Accuracy, Utilization, and Research

  2008cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Complications DOI: 10.1111/j.1464-5491.2009.02667.x Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor

  2008cited by this paper
• Liraglutide, a once-daily human GLP-1 analogue

  2008cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  2006cited by this paper
• Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

  2006cited by this paper
• Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.

  2005cited by this paper
• Therapeutic strategies based on glucagon-like peptide 1.

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• The burden of treatment failure in type 2 diabetes.

  2004cited by this paper
• Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*

  2002cited by this paper
• Ask the Editor

  2001cited by this paper
• Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment

  1996cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper
• 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels

  year unknowncited by this paper

• Development of a Patient Decision Aid on the Choice of Diabetes Medication for Filipino Patients with Type 2 Diabetes Mellitus

  2019cites this paper
• Comparison of trajectories of self‐monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly

  2016cites this paper